IDRA
NASDAQIdera Pharmaceuticals Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
Latest news
25 items- SECSEC Form 15-12G filed by Idera Pharmaceuticals Inc.15-12G - Aceragen, Inc. (0000861838) (Filer)
- SECSEC Form EFFECT filed by Idera Pharmaceuticals Inc.EFFECT - Aceragen, Inc. (0000861838) (Filer)
- SECSEC Form EFFECT filed by Idera Pharmaceuticals Inc.EFFECT - Aceragen, Inc. (0000861838) (Filer)
- SECSEC Form EFFECT filed by Idera Pharmaceuticals Inc.EFFECT - Aceragen, Inc. (0000861838) (Filer)
- SECSEC Form EFFECT filed by Idera Pharmaceuticals Inc.EFFECT - Aceragen, Inc. (0000861838) (Filer)
- SECSEC Form EFFECT filed by Idera Pharmaceuticals Inc.EFFECT - Aceragen, Inc. (0000861838) (Filer)
- SECSEC Form EFFECT filed by Idera Pharmaceuticals Inc.EFFECT - Aceragen, Inc. (0000861838) (Filer)
- SECSEC Form EFFECT filed by Idera Pharmaceuticals Inc.EFFECT - Aceragen, Inc. (0000861838) (Filer)
- SECSEC Form EFFECT filed by Idera Pharmaceuticals Inc.EFFECT - Aceragen, Inc. (0000861838) (Filer)
- SECSEC Form EFFECT filed by Idera Pharmaceuticals Inc.EFFECT - Aceragen, Inc. (0000861838) (Filer)
- SECSEC Form EFFECT filed by Idera Pharmaceuticals Inc.EFFECT - Aceragen, Inc. (0000861838) (Filer)
- SECSEC Form EFFECT filed by Idera Pharmaceuticals Inc.EFFECT - Aceragen, Inc. (0000861838) (Filer)
- SECSEC Form EFFECT filed by Idera Pharmaceuticals Inc.EFFECT - Aceragen, Inc. (0000861838) (Filer)
- SECSEC Form EFFECT filed by Idera Pharmaceuticals Inc.EFFECT - Aceragen, Inc. (0000861838) (Filer)
- SECSEC Form EFFECT filed by Idera Pharmaceuticals Inc.EFFECT - Aceragen, Inc. (0000861838) (Filer)
- SECSEC Form EFFECT filed by Idera Pharmaceuticals Inc.EFFECT - Aceragen, Inc. (0000861838) (Filer)
- SECSEC Form EFFECT filed by Idera Pharmaceuticals Inc.EFFECT - Aceragen, Inc. (0000861838) (Filer)
- SECSEC Form EFFECT filed by Idera Pharmaceuticals Inc.EFFECT - Aceragen, Inc. (0000861838) (Filer)
- SECSEC Form EFFECT filed by Idera Pharmaceuticals Inc.EFFECT - Aceragen, Inc. (0000861838) (Filer)
- SECSEC Form POS AM filed by Idera Pharmaceuticals Inc.POS AM - Aceragen, Inc. (0000861838) (Filer)
- SECSEC Form S-8 POS filed by Idera Pharmaceuticals Inc.S-8 POS - Aceragen, Inc. (0000861838) (Filer)
- SECSEC Form S-8 POS filed by Idera Pharmaceuticals Inc.S-8 POS - Aceragen, Inc. (0000861838) (Filer)
- SECSEC Form POS AM filed by Idera Pharmaceuticals Inc.POS AM - Aceragen, Inc. (0000861838) (Filer)
- SECSEC Form POS AM filed by Idera Pharmaceuticals Inc.POS AM - Aceragen, Inc. (0000861838) (Filer)
- SECSEC Form S-8 POS filed by Idera Pharmaceuticals Inc.S-8 POS - Aceragen, Inc. (0000861838) (Filer)
IDRA FAQ
5 questionsWhat does Idera Pharmaceuticals Inc. do?
Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology and rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration and supply agreement with AbbVie Inc. and Bristol-Meyers Squibb. Idera Pharmaceuticals...Where does IDRA stock trade?
Idera Pharmaceuticals Inc. (IDRA) is listed on NASDAQ.What sector and industry is IDRA in?
Idera Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What companies are similar to IDRA?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare IDRA side-by-side with any of them on Quantisnow.How can I track IDRA on Quantisnow?
Quantisnow aggregates Idera Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IDRA to receive live email and push alerts on every new disclosure.